19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace.

SCAMHC serves all individuals regardless of inability to pay. Discounts for essential services are offered based on family size and income. For more information, contact (334) 222-2523 or our 24/7 Helpline at 1-877-530-0002.

 

 


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Many Marijuana Vendors Aim Advertising at Kids: StudyHeart Function Rebounds for Kids With COVID-Linked MIS-CWhich Kids Are Most Vulnerable to Severe COVID-19?At-Home COVID Tests Accurate for Ki​ds: StudyCDC Study Shows Power of Flu Vaccine for KidsCOVID Hospitalizations Rising in Kids Too Young for VaccineNearly 600,000 U.S. Kids Had COVID Last WeekWhite House to Give Schools 10 Million Free COVID Tests Every MonthKids' Behavior Worsened With Remote Learning: StudyLater School Start Times Boost Parents' Health, TooUrban Air Pollution Drives Millions of Cases of Asthma in KidsCDC Backs Boosters for High-Risk Kids Aged 5-11, Shorter Time Between ShotsA Better Way to Correct Severe Scoliosis in Kids?Getting Your Child Their Vaccine?  Some Tips on Easing Needle FearsU.S. Hospitals Seeing Record Numbers of Young COVID PatientsSevere Illness in Children Brings Hardship for FamiliesReal-World Data Confirms Pfizer Vaccine Safe for Kids Ages 5-11Family Factors Affect Child's Odds for Cleft PalateAs Omicron Spreads, Child Hospitalizations Climb 30% in Past WeekNew Clues to Sudden Unexplained Deaths in Young KidsSevere Illness in a Child Takes Big Toll on Parents, Siblings: StudyProgram Aims to Get Lifesaving Drugs to Kids With Cancer in Poorer CountriesSchool COVID Outbreaks Drop When Adults Wear Masks, Study FindsMany Overweight Kids Already Have Hardened Arteries, DiabetesCDC Supports 'Test-to-Stay' Strategy for SchoolsJunk Food Ads Reaching Kids Through Livestream Gaming PlatformsWhat Does 'Long COVID' Look Like in Kids?New Drug a Good Treatment Option for Severe Asthma in KidsFebrile Seizures: How to Protect Your ChildNew Treatment Greatly Boosts Survival for Kids With a Rare, Aggressive CancerRisk of Vision Trouble Rises in Children With Type 2 DiabetesMore Time Outdoors May Lower Risk of MS in YouthNew Asthma Drug Helps Kids, But Price Tag Is HighUS Surgeon General Report Warns of Mental Health Crisis Hitting YouthAnother Benefit to Asthma Control for Kids: Less Bullying1 in 3 U.S. Children Lack Adequate Health InsuranceWhat's Behind Unexplained Epilepsy in Kids? A Gene Test May TellIs the Mumps Vaccine Becoming Less Effective?Autism Now Diagnosed in 1 in Every 44 Children, CDC SaysKids With Uncontrolled Asthma at Higher Odds for Severe COVID-19Nearly 7% of U.S. Kids Have Had a Head Injury or ConcussionAre Your Holiday Gifts on the 'Noisy Toy List'?Many Kids, Teens Think Girls Don't Care About Computer ScienceMost Parents Say Their Kids Aren't Thankful Enough: PollPandemic Curbed Kids' Efforts to Lose Excess WeightClimate Change May Not Increase Allergies in Kids With Asthma: StudyNearly 10% of Younger Kids Have Gotten First COVID Vaccine DoseAHA News: Family-Based Programs Targeting Childhood Obesity Can Be Good for Parents, TooCases of Children's Severe COVID-Linked Illness Were Worse in Second WaveFace Masks Don't Hide Emotions From Kids: Study
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

New Treatment Greatly Boosts Survival for Kids With a Rare, Aggressive Cancer

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: Dec 10th 2021

new article illustration

FRIDAY, Dec. 10, 2021 (HealthDay News) -- Children with the rare cancer neuroblastoma often succumb to the disease despite aggressive treatment. But researchers have found that adding an experimental antibody to that treatment, right off the bat, may improve their outlook.

Of 64 children treated with the antibody in a clinical trial, 74% were still alive and free of a recurrence three years later. That compares with historical rates of around 50% with conventional treatment alone.

The antibody, known as hu14.18K322A, remains experimental, and is not yet available as a treatment, said Dr. Wayne Furman, the lead researcher on the trial.

The Children's Oncology Group, a government-funded clinical trials group, is planning a larger study to test the tactic of early antibody therapy -- with either hu14.18K322A, or another drug, Furman said.

Neuroblastoma is a cancer that begins in immature nerve cells, and primarily affects babies and children younger than 5. Each year, about 800 children in the United States are diagnosed with the disease, according to the American Cancer Society.

Roughly half of them are diagnosed after the cancer has spread and is considered "high risk."

At that point, aggressive treatment is needed. The typical regimen starts with high-dose chemotherapy, followed by surgery to remove any remaining visible tumors. Next comes additional chemo, followed by a stem cell transplant to rebuild the immune system, and then radiation.

In more recent years, doctors have added another weapon to the end of that regimen: the monoclonal antibody drug dinutuximab. The drug latches onto GD2, a protein on the surface of many neuroblastoma cells. It's given along with certain immune system proteins, in the hopes of boosting the child's immune response to cancer cells that have survived the treatment onslaught.

Dinutuximab has made a difference: One trial found that after two years, 66% of children given the drug were recurrence-free, compared with 46% of those on standard treatment alone.

But dinutuximab has been given at the tail end of treatment, said Furman, an oncologist at St. Jude Children's Research Hospital in Memphis, Tenn.

That was based on the belief that giving it early, during the initial high-dose chemo, would zap its effectiveness -- because the chemo suppresses the immune system.

"But we've been learning more and more about the immune system," Furman said.

Studies of adults with certain cancers, for example, have found that combining antibody therapy with chemo -- a concept called chemoimmunotherapy -- improved patients' responses. And a recent Children's Oncology Group trial found that adding dinutuximab to chemo showed "significant anti-tumor activity" in children whose neuroblastoma had come back.

Furman's team reasoned that giving an anti-GD2 antibody straight away, instead of waiting, might do the same for children newly diagnosed with high-risk neuroblastoma.

Instead of dinutuximab, though, they used the experimental antibody, developed at St. Jude. It also targets GD2, but was designed to limit a primary side effect of dinutuximab: pain.

Children in the trial received six rounds of chemo, along with infusions of the antibody therapy. They then moved on to other standard treatments, including additional antibody infusions.

While the experimental antibody was designed to cause less pain, the children still needed infusions of opioid painkillers during treatment. Pain was the most common side effect tied to the antibody -- reported in 10% of treatment cycles.

After three years, 86% of the children were still alive, with 74% recurrence-free.

Furman said that in 30 years of treating kids with high-risk neuroblastoma, those are the best outcomes he has seen.

It is not clear whether all of those recurrence-free children are cured; it's possible the treatment delays recurrence in some, according to Furman. The hope, of course, is that the results hold up.

"This is a very important and provocative study building on recent advances with chemoimmunotherapy for children with relapsed neuroblastoma in the Children's Oncology Group," said Dr. John Maris, chair of neuroblastoma research at Children's Hospital of Philadelphia.

Like Furman, he pointed to the COG trial that will test the approach in newly diagnosed children.

"If confirmed, chemoimmunotherapy would become standard therapy and hopefully, significant improve chances for cure of high-risk neuroblastoma," said Maris, who wasn't part of the research.

Furman said children in his study received the experimental antibody at a dose more than double the maximum approved dose of dinutuximab. It's unclear, he said, whether the children's outcomes are related to the higher dose, or because hu14.18K322A is "a better antibody."

The study -- published Dec. 6 in Journal of Clinical Oncology, was funded by federal and foundation grants. The experimental antibody is now owned by EMD Serono, a division of drug maker Merck.

More information

The American Cancer Society has a primer on neuroblastoma.

SOURCES: Wayne Furman, MD, oncologist, St. Jude Children's Research Hospital, Memphis, Tenn.; John Maris, MD, pediatric oncologist and chairman, neuroblastoma research, Children's Hospital of Philadelphia; Journal of Clinical Oncology, online, Dec. 6, 2021